



MEDICAL POLICY UPDATE

FOR PROFESSIONAL AND FACILITY PROVIDERS



September 2021

In This Issue

REMINDER: Laboratory Management Coverage Guidelines	2
Coverage Guidelines Revised for Fulvestrant (Faslodex).....	2
Biosimilar Preferred Products Established for Bevacizumab, Rituximab, and Trastuzumab	5
Reinstatement of Oncology Policies.....	5
Contents.....	10

Policy

Coverage Guidelines Revised for Infliximab



Highmark West Virginia has revised criteria for infliximab products [Infliximab (Remicade®), Infliximab-axxq (Avsola™), infliximab-dyyb (Inflectra®) and infliximab-abda (Renflexis®)]. The initial authorization period will be for six (6) months. The preferred products will apply to all indications. The requirement to try and fail at least two (2) immunosuppressants or all immunosuppressants are contraindicated will be removed from the Crohn’s disease indication.

This revised Medical Policy will apply to professional providers and facility claims. The effective date is January 1, 2022.

Place of Service:

Please refer to Medical Policy I-28, Infliximab, for additional information.

REMINDER: Laboratory Management Coverage Guidelines



Highmark West Virginia is providing a reminder to all providers.

The Laboratory Management coverage guidelines will be updated and take effect January 1, 2022. This applies to both professional provider and facility claims.

At that time, coverage guidelines can be accessed utilizing the live link from the Medical Policy website.

REMINDER: Cardiology & Radiology Imaging Coverage Guidelines



Highmark West Virginia is providing a reminder to all providers.

The Cardiology & Radiology Imaging coverage guidelines will be updated and take effect January 1, 2022. This applies to both professional provider and facility claims.

At this time, coverage guidelines can be accessed utilizing the live link from the medical policy website.

Coverage Guidelines Revised for Fulvestrant (Faslodex)



Highmark West Virginia has revised criteria/established new criteria for Fulvestrant (Faslodex).

Criteria for Breast Cancer, Inflammatory has been added to the policy to include the following:

- When used as therapy for individuals with no response to preoperative systemic therapy or treatment for recurrent unresectable (local or regional) or stage IV (M1) hormone receptor (HR)-positive, in postmenopausal women* or for premenopausal women treated with ovarian ablation/suppression.
 - o As first-line or second-line therapy and beyond as a single agent for human epidermal growth factor receptor 2 (HER2)-negative disease with no visceral crisis (preferred regimen**); **or**
 - o As first-line therapy in combination with a non-steroidal aromatase inhibitor (anastrozole or letrozole) for HER2-negative disease with no visceral crisis (preferred regimen**); **or**
 - o As first-line therapy in combination with a CDK 4/6 inhibitor (abemaciclib, palbociclib or ribociclib) for HER2-negative disease with no visceral crisis (all preferred regimens**); **or**
 - o As second-line therapy and beyond in combination with everolimus for HER2-negative disease with no visceral crisis (preferred regimen**); **or**
 - o As a second-line therapy and beyond in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib or ribociclib) for HER-2 negative disease with no

- visceral crisis if a CDK4/6 inhibitor was not previously used (preferred regimen**); **or**
- o As second-line therapy and beyond in combination with alpelisib for HER2-negative disease with no visceral crisis if PIK3CA activating mutation positive (preferred regimen**); **or**
 - o Therapy as a single agent for HER2- positive disease; **or**
 - o When used in combination with trastuzumab for the treatment of HER2-positive disease

Criteria for Breast Cancer, Invasive has been revised to include the following:

- When used as therapy for individuals with recurrent unresectable (local or regional) or stage IV (M1) hormone receptor (HR)-positive, in postmenopausal women* or for premenopausal women treated with ovarian ablation/suppression.
 - o As second-line therapy and beyond in combination with alpelisib for HER2-negative disease with no visceral crisis if PIK3CA activating mutation positive (preferred regimen**)

Criteria for Endometrial Carcinoma has been revised to include the following:

- When used as primary treatment as single-agent hormone therapy for grade one (1) or two (2) endometrioid histologies, preferably in individuals with small tumor volume or an indolent growth pace in **ANY** of the following:
 - o With sequential EBRT and with or without brachytherapy for locoregional extrauterine disease that is not suitable for primary surgery; **or**
 - o With or without stereotactic body radiation therapy and/or EBRT for distant metastases that are suitable for primary surgery, **or**
 - o For distant metastases that are not suitable for primary surgery; **or**
- When used as adjuvant treatment for surgically staged individuals as single-agent hormone therapy for grade one (1) or two (2) endometrioid histologies, preferably in individuals with small tumor volume or an indolent growth pace
 - o With sequential EBRT with or without vaginal brachytherapy for stage II disease; **or**
 - o With or without EBRT and with or without vaginal brachytherapy for stage III-IV-disease; **or**
- When used as single-agent hormone therapy for grade one (1) or two (2) endometrioid histologies, preferably in individuals with small tumor volume or an indolent growth pace in **ANY** of the following:
 - o With sequential EBRT with or without brachytherapy for local/regional recurrence in individuals with no prior RT to site of recurrence, or previous brachytherapy only; **or**
 - o After surgical exploration, with sequential EBRT for local/regional recurrence in individuals with disease confined to the vagina or paravaginal soft tissues, or in pelvic, para-aortic or common iliac lymph nodes; **or**
 - o After surgical exploration, with or without sequential tumor-directed EBRT for local-regional recurrence in individuals with microscopic residual upper abdominal or peritoneal disease

Criteria for Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer-Low-grade serous carcinoma/Ovarian borderline epithelial Tumors (Low Malignant Potential with invasive implants has been updated to include the following:

- When used as hormone therapy as a single agent (useful in certain circumstances) for disease persistence or recurrence of low-grade serous carcinoma:
 - When used as immediate treatment for serially rising CA-125 in individuals that previously received chemotherapy; **or**
 - When used for progression on primary, maintenance, or recurrence therapy (platinum-resistant disease); **or**
 - When used for stable or persistent disease (if not on maintenance therapy) (platinum-resistant disease); **or**
 - When used for complete remission and relapse less than six (6) months after completing chemotherapy (platinum-resistant disease); **or**
 - When used for radiographic and/or clinical relapse in individuals with previous complete remission and relapse six (6) months or greater after completing prior chemotherapy (platinum-sensitive disease)

Criteria for uterine sarcoma has been revised to include the following:

- When used as therapy for low-grade endometrial stromal sarcoma (ESS) or estrogen receptor/progesterone receptor positive (ER/PR+) uterine leiomyosarcoma (uLMS) preferable in individuals with small tumor volume or an indolent growth pace:
 - Following total hysterectomy with bilateral salpingo-oophorectomy for stage II-IV low-grade ESS; **or**
 - Consider following total hysterectomy with or without bilateral salpingo-ooporectomy (TH± BSO) for stage II-III ER/PR +uLMS; **or**
 - Following **TH ± BSO** for stage IV ER/PR+ uLMS; **or**
 - For unresectable isolated metastases or disseminated metastases.

This revised Medical Policy will apply to professional providers and/or facility claims. The effective date is December 27, 2021.

Place of Service: Outpatient

Please refer to Medical Policy I-123, Fulvestrant (Faslodex), for additional information.

Biosimilar Preferred Products Established for Bevacizumab, Rituximab, and Trastuzumab



Highmark's Medicare Advantage product has established preferred products for bevacizumab, rituximab and trastuzumab. The preferred products are for oncologic indications when initiating therapy (no use in the previous 365 days) and are as follows:

- Bevacizumab
 - Zirabev®
 - Mvasi®
- Trastuzumab
 - Trazimera™
 - Kanjinti™
- Rituximab
 - Ruxience™
 - Riabni™

This revised Medical Policy will apply to professional providers and facility claims. The effective date is January 1, 2022.

Place of Service: Outpatient

Please refer to Medical Policies I-38, Rituximab, I-208, Billing and Coding for Chemotherapy, I-211, Trastuzumab Biosimilars and I-75, Bevacizumab (Avastin) and Bevacizumab Biosimilars, N-104, Anti-Cancer Chemotherapy for Colorectal Cancer - NCD 110.17 for additional information.

Reinstatement of Oncology Policies



Due to the removal of coding directive from Local Coverage Article: Billing and Coding: Chemotherapy (A56141) Highmark's Medicare Advantage product will reestablish guidelines for the Food and Drug Administration (FDA) approved indications and for treatment of any of the current category 1, 2A, or 2B compendia recommendations (NCCN, Clinical Pharmacology, MicroMedex, AHFS, Lexi-Comp, etc.) related to the following medications:



- J9047 – carfilzomib (Kyprolis)
- J9355 – trastuzumab (Herceptin)
- J9400 – ziv-aflibercept (Zaltrap)
- J9354 – ado-trastuzumab emtansine (Kadcyla)
- J9306 – pertuzumab (Perjeta)
- J9302 – ofatumumab (Arzerra)
- J9179 – erbulin mesylate (Halaven)
- J9207 – ixabepilone (Ixempra)
- J9042 – brentuximab vedotin (Adcetris)
- J9301 – Obinutuzumab (Gazyva)
- J9308 – ramucirumab (Cyramza)
- J9145 – daratumumab (Darzalex)
- J9032 – belinostat (Beleodaq)

J9315 – romidepsin (Istodaz)
 J9285 – olaratumab (Lartruvo)
 J9176 – elotuzumab (Empliciti)
 J9295 – necitumumab (Portrazza)
 J9352 – trabectedin (Yondelis)
 J9229 – inotuzumab ozogamicin (Besponsa)
 J9057 – copanlisib (Aliqopa)
 J9153 – cytarabine liposome/daunorubicin liposome (Vyxeos)
 J9228 – ipilimumab (Yervoy)
 J9203 – gemtuzumab ozogamicin (Mylotarg)
 J9205 – irinotecan liposome (Onivyde)
 J9039 – blinatumomab (Blinicyto)
 J9034 – bendamustine (Bendeka)
 J9044 – bortezomib
 J9022 – atezolizumab (Tecentriq)
 J9023 – avelumab (Bavencio)
 J9173 – durvalumab (Imfinzi)
 J9271 – pembrolizumab (Keytruda)
 J9299 – nivolumab (Opdivo)
 J9019 – asparaginase (Erwinaze)
 J9204 – mogamulizumab-kpkc (Poteligeo)
 J9356 – trastuzumab and hyaluronidase-oysk (Herceptin Hylecta)

These medical policies will apply to professional providers and facility claims. The effective dates are on or after November 11, 2021.

Place of Service:

Please refer to Medicare Advantage Medical Policies impacted by the above codes:

WVMA I-57 Carfilzomib (Kyprolis)
 WVMA I-84 Trastuzumab (Herceptin)
 WVMA I-112 Ziv-aflibercept (Zaltrap)
 WVMA I-113 Ado-trastuzumab emtansine (Kadcyla)
 WVMA I-115 Pertuzumab (Perjeta)
 WVMA I-116 Ofatumumab (Arzerra)
 WVMA I-119 Erbulin mesylate (Halaven)
 WVMA I-133 Ixabepilone (Ixempra)
 WVMA I-136 Brentuximab vedotin (Adcetris)
 WVMA I-137 Obinutuzumab (Gazyva)
 WVMA I-148 Ramucirumab (Cyramza)
 WVMA I-150 Daratumumab (Darzalex)
 WVMA I-159 Oncologic Indications for Histone Deacetylase (HDAC) Inhibitors
 WVMA I-162 Olaratumab (Lartruvo)
 WVMA I-166 Elotuzumab (Empliciti)
 WVMA I-168 Necitumumab (Portrazza)
 WVMA I-169 Trabectedin (Yondelis)
 WVMA I-185 Inotuzumab ozogamicin (Besponsa)
 WVMA I-191 Copanlisib (Aliqopa)
 WVMA I-193 Cytarabine liposome/daunorubicin liposome (Vyxeos)
 WVMA I-59 Ipilimumab (Yervoy)
 WVMA I-161 Irinotecan liposome (Onivyde)
 WVMA I-127 Blinatumomab (Blinicyto)
 WVMA I-120 Programmed Death Receptor (PD-1)/ Programmed Death-Ligand (PD-L1) Blocking Antibodies

WVMA I-158 Pegaspargase (Oncaspar), Asparaginase Erwinia Chrysanthemi (Erwinaze), and Calaspargase Pegol-mknl (Asparlas)

WVMA I-214 Trastuzumab and Hyaluronidase-oysk (Herceptin Hylecta, for additional information).

Coverage Guidelines Revised for Fulvestrant (Faslodex)



NEWS FOR ALL
PROVIDER TYPES



MA
MEDICARE
ADVANTAGE

Highmark's Medicare Advantage product has revised criteria/established new criteria for Fulvestrant (Faslodex).

Criteria for Breast Cancer, Inflammatory has been added to the policy to include the following:

- When used as therapy for individuals with no response to preoperative systemic therapy or treatment for recurrent unresectable (local or regional) or stage IV (M1) hormone receptor (HR)-positive, in postmenopausal women* or for premenopausal women treated with ovarian ablation/suppression.
 - As first-line or second-line therapy and beyond as a single agent for human epidermal growth factor receptor 2 (HER2)-negative disease with no visceral crisis (preferred regimen**); **or**
 - As first-line therapy in combination with a non-steroidal aromatase inhibitor (anastrozole or letrozole) for HER2-negative disease with no visceral crisis (preferred regimen**); **or**
 - As first-line therapy in combination with a CDK 4/6 inhibitor (abemaciclib, palbociclib or ribociclib) for HER2-negative disease with no visceral crisis (all preferred regimens**); **or**
 - As second-line therapy and beyond in combination with everolimus for HER2-negative disease with no visceral crisis (preferred regimen**); **or**
 - As a second-line therapy and beyond in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib or ribociclib) for HER-2 negative disease with no visceral crisis if a CDK4/6 inhibitor was not previously used (preferred regimen**); **or**
 - As second-line therapy and beyond in combination with alpelisib for HER2-negative disease with no visceral crisis if PIK3CA activating mutation positive (preferred regimen**); **or**
 - Therapy as a single agent for HER2- positive disease; **or**
 - When used in combination with trastuzumab for the treatment of HER2-positive disease

Criteria for Breast Cancer, Invasive has been revised to include the following:

- When used as therapy for individuals with recurrent unresectable (local or regional) or stage IV (M1) hormone receptor (HR)-positive, in postmenopausal women* or for premenopausal women treated with ovarian ablation/suppression.

- As second-line therapy and beyond in combination with alpelisib for HER2-negative disease with no visceral crisis if PIK3CA activating mutation positive (preferred regimen**)

Criteria for Endometrial Carcinoma has been revised to include the following:

- When used as primary treatment as single-agent hormone therapy for grade one (1) or two (2) endometrioid histologies, preferably in individuals with small tumor volume or an indolent growth pace in **ANY** of the following:
 - With sequential EBRT and with or without brachytherapy for locoregional extrauterine disease that is not suitable for primary surgery; **or**
 - With or without stereotactic body radiation therapy and/or EBRT for distant metastases that are suitable for primary surgery, **or**
 - For distant metastases that are not suitable for primary surgery; **or**
- When used as adjuvant treatment for surgically staged individuals as single-agent hormone therapy for grade one (1) or two (2) endometrioid histologies, preferably in individuals with small tumor volume or an indolent growth pace
 - With sequential EBRT with or without vaginal brachytherapy for stage II disease; **or**
 - With or without EBRT and with or without vaginal brachytherapy for stage III-IV-disease; **or**
- When used as single-agent hormone therapy for grade one (1) or two (2) endometrioid histologies, preferably in individuals with small tumor volume or an indolent growth pace in **ANY** of the following:
 - With sequential EBRT with or without brachytherapy for local/regional recurrence in individuals with no prior RT to site of recurrence, or previous brachytherapy only; **or**
 - After surgical exploration, with sequential EBRT for local/regional recurrence in individuals with disease confined to the vagina or paravaginal soft tissues, or in pelvic, para-aortic or common iliac lymph nodes; **or**
 - After surgical exploration, with or without sequential tumor-directed EBRT for local-regional recurrence in individuals with microscopic residual upper abdominal or peritoneal disease

Criteria for Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer-Low-grade serous carcinoma/Ovarian borderline epithelial Tumors (Low Malignant Potential with invasive implants has been updated to include the following:

- When used as hormone therapy as a single agent (useful in certain circumstances) for disease persistence or recurrence of low-grade serous carcinoma:
 - When used as immediate treatment for serially rising CA-125 in individuals that previously received chemotherapy; **or**
 - When used for progression on primary, maintenance, or recurrence therapy (platinum-resistant disease); **or**
 - When used for stable or persistent disease (if not on maintenance therapy) (platinum-resistant disease); **or**
 - When used for complete remission and relapse less than six (6) months after completing chemotherapy (platinum-resistant disease); **or**
 - When used for radiographic and/or clinical relapse in individuals with previous complete remission and relapse six (6) months or greater after completing prior chemotherapy (platinum-sensitive disease)

Criteria for uterine sarcoma has been revised to include the following:

- When used as therapy for low-grade endometrial stromal sarcoma (ESS) or estrogen receptor/progesterone receptor positive (ER/PR+) uterine leiomyosarcoma (uLMS) preferable in individuals with small tumor volume or an indolent growth pace:
 - Following total hysterectomy with bilateral salpingo-oophorectomy for stage II-IV low-grade ESS; **or**
 - Consider following total hysterectomy with or without bilateral salpingo-ooporectomy (TH± BSO) for stage II-III ER/PR +uLMS
 - Following **TH** ± BSO for stage IV ER/PR+ uLMS
 - For unresectable isolated metastases or disseminated metastases

This revised Medical Policy will apply to professional providers and/or facility claims. The effective date is December 27, 2021.

Please refer to Medical Policy MA I-123, Fulvestrant (Faslodex), for additional information.

Comments on these new medical policies?

We want to know what you think about our new medical policy changes. Send us an email with any questions or comments that you may have on the new medical policies in this edition of *Medical Policy Update*.

Write to us at medicalpolicy@highmark.com.

Contents

Coverage Guidelines Revised for Infliximab	1
REMINDER: Laboratory Management Coverage Guidelines	2
Coverage Guidelines Revised for Fulvestrant (Faslodex)	2
Biosimilar Preferred Products Established for Bevacizumab, Rituximab, and Trastuzumab	5
Reinstatement of Oncology Policies	5
Coverage Guidelines Revised for Fulvestrant (Faslodex)	7
Comments on these new medical policies?	10
Contents	10



Save yourself valuable time with [e-Subscribe!](#) Sign up today and you'll begin receiving email notifications with a direct link to the latest issue of *Medical Policy Update*.

About this newsletter

Medical Policy Update is the monthly newsletter for most health care professionals (and office staff) and facilities who participate in our networks and submit claims to Highmark using the 837P HIPAA transaction or the CMS 1500 form, or the 837I HIPAA transaction.

Medical Policy Update focuses only on medical policy and claims administration updates, including coding guidelines and procedure code revisions, and is the sole source for this information. For all other news, information and updates, be sure to read *Provider News*, available on the Provider Resource Center at www.highmarkbcbswv.com.

Inquiries about Eligibility, Benefits, Claims Status or Authorizations

For inquiries about eligibility, benefits, claim status or authorizations, Highmark encourages providers to use the electronic resources available to them - Navinet® and the applicable HIPAA transactions – prior to placing a telephone call to the Provider Service Center at 1-800-242-0514.

Acknowledgement

The five-digit numeric codes that appear in *Medical Policy Update* were obtained from the *Current Procedural Terminology (CPT)*, as contained in CPT-2021, Copyright 2020, by the American Medical Association. *Medical Policy Update* includes *CPT* descriptive terms and numeric procedure codes and modifiers that are copyrighted by the American Medical Association. These procedure codes and modifiers are used for reporting medical services and procedures.